Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers. Significant
efforts have largely defined major genetic factors driving PDAC pathogenesis and …

Patients with localized pancreatic ductal adenocarcinoma (PDAC) are best treated with
surgical resection of the primary tumour and systemic chemotherapy, which provides …

Each tumour contains diverse cellular states that underlie intratumour heterogeneity (ITH), a
central challenge of cancer therapeutics. Dozens of recent studies have begun to describe …

Transcriptional heterogeneity among malignant cells of a tumor has been studied in
individual cancer types and shown to be organized into cancer cell states; however, it …

Pancreatic ductal adenocarcinoma (PDAC) has a rising incidence and is one of the most
lethal human malignancies. Much is known regarding the biology and pathophysiology of …

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal and treatment-refractory
cancer. Molecular stratification in pancreatic cancer remains rudimentary and does not yet …

Abstract Cancer-associated fibroblasts (CAFs), a stromal cell population with cell-of-origin,
phenotypic and functional heterogeneity, are the most essential components of the tumor …

Pancreatic ductal adenocarcinoma (PDAC) is a clinically challenging cancer, due to both its
late stage at diagnosis and its resistance to chemotherapy. However, recent advances in our …

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer that is most frequently
detected at advanced stages, limiting treatment options to systemic chemotherapy with …

The response to tumor-initiating inflammatory and genetic insults can vary among
morphologically indistinguishable cells, suggesting as yet uncharacterized roles for …